Brad Martin, currently working for Neurotech as the Vice President, Market Access, Specialty Trade and Distribution. Brad has over 23 years of experience in the Bio Pharmaceutical Industry focused on CNS, Rare and Orphan Diseases. Brad has also worked at Sarepta Therapeutics where he was part of market access team, developing the trade and distribution strategy for Sarepta’s one-time gene therapy for Duchenne Muscular Dystrophy. Prior to Sarepta, Brad was at AveXis and focused on the pre-commercial strategy and implementation of a successful launch for market access, reimbursement, and distribution. Over the last seven years, he has been at the forefront in key discussions with large commercial payers, PBMs, government payers, specialty pharmacies, hospital systems, and consortiums evaluating paying for one-time innovative treatments, as well as solving for temperature-controlled distribution of gene and cell therapies.